Loading…
← CockpitCompetitor Analysis › COHANCE.NS Cohance LifesciencesOpen in the cockpit ↗

Cohance LifesciencesCOHANCE.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

CDMO manufacturing pharmaceutical intermediates, APIs and specialty chemicals for global pharma and life-sciences companies.

≈ A newer Indian pharma/specialty-chemical CDMOMomentum neutral 59
Mkt cap
$1.87B
US dollars, full cap
Free float
36%
of shares outstanding
$/day
$3.17M
20-day average traded
Fwd P/E
96.3×
forward earnings
ROIC−WACC
-14.9 pp
WACC 15.5%
Hurdle
n/a
no reverse DCF
Next earnings
82 days
8 Feb 2027
Close · INR₹456.40
1D+1.1%
1W-1.7%
1M-0.3%
3M+0.3%
6M+6.5%
YTD-13.7%
1Y-33.9%
ATR %4.0%
Beta0.79
52w lowhigh32.5% off high

What Cohance Lifesciences does

CDMO manufacturing pharmaceutical intermediates, APIs and specialty chemicals for global pharma and life-sciences companies.

In one line: A newer Indian pharma/specialty-chemical CDMO.

Products and services

  • Pharma intermediates/APIs
  • Specialty chemical CDMO
  • Contrast media intermediates

Customers

  • Global pharma companies
  • Specialty chemical buyers

Where it sits in the supply chain

  • Chemical synthesis R&D
  • API/intermediate manufacturing
  • CDMO services for global pharma

What could go right

  • Global pharma outsourcing (China+1) growth
  • New CDMO contract wins

What could go wrong

  • Customer concentration
  • Chemical raw material cost swings

Moat: narrow (process know-how, regulatory licence). Regulated manufacturing plants and multi-year CDMO contracts create switching costs for pharma clients.

Headquarters: Hyderabad, India · Employees: 5,051

Named competitors

Cohance Lifesciences at a glance

Size Cohance Lifesciences (COHANCE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.87B, the 396th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹456.40 on 18 Nov 2026.

Performance Over six months the shares gained 6.5%, against -12.4% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 13.7% over the last twelve months (peer median +9.4%); the operating margin is 1.6% (peer median 15.0%).

Valuation It trades at 96.3× forward earnings against a peer median of 15.7× (2nd most expensive of 20).

Capital Return on invested capital runs 14.9 points below its cost of capital (15.5% WACC).

Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026COHANCE.NS 109Peer median 89
Six months, rebased to 100: Cohance Lifesciences against the median of its 20 peers (local-currency closes).

Cohance Lifesciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹20.6B₹22.4B₹25.7B₹10.4B₹13.3B
Revenue growth—-13%+148%-22%—
Gross profit₹6.98B₹4.85B₹8.64B₹4.38B₹5.87B
EBITDA₹2.31B₹4.15B₹8.06B₹4.05B₹5.84B
Net income₹474M₹1.79B₹4.87B₹3.00B₹4.11B
Free cash flown/a₹1.35B₹3.31B₹3.29B₹1.66B
Capital expendituren/a₹2.20B₹3.17B₹519M₹2.86B
Total debt₹4.48B₹4.00B₹4.86B₹650M₹703M

Quarterly statements and history in the cockpit →

Cohance Lifesciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%600211300009PFIZER000908DMPALIVUS300573605507SHILPAMED000028ZYME0512RARE30101545406002010023993933HRMYONESOURCECOHANCE.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Cohance Lifesciences is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×600211300009PFIZERDMP300573SHILPAMED000028ZYME6002010023993933ONESOURCECOHANCE.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cohance Lifesciences is the large dot.

Cohance Lifesciences competitors and peer comparison

Head to head with its named competitors (COHANCE.NS vs NEULANDLAB.NS vs DIVISLAB.NS vs PPLPHARMA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Cohance Lifesciences COHANCE.NS$1.87B+7%+14%2%96.3×n/a
Neuland Laboratories NEULANDLAB.NS$2.95B+28%+50%26%63.4×n/a
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a

How Cohance Lifesciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cohance Lifesciences against its 20 peers (data as of 18 Nov 2026)
MeasureCOHANCE.NSPeer medianRank in peer set
1-month return-0.3%+0.7%10th lowest of 21
6-month return+6.5%-12.4%3rd highest of 21
Distance from 52-week high-32.5%-27.6%9th lowest of 21
Revenue growth (TTM)+13.7%+9.4%7th highest of 21
Operating margin1.6%15.0%3rd lowest of 21
Forward P/E96.3×15.7×2nd most expensive of 20
ROIC minus cost of capital-14.9 pp+0.7 pp3rd lowest of 21
EV / EBITDA76.7×11.6×most expensive of 11
Net debt / EBITDA0.7×1.1×5th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a

Questions

Who are Cohance Lifesciences's main competitors?
Named competitors: Neuland Laboratories (NEULANDLAB.NS), Divi's Laboratories (DIVISLAB.NS), Piramal Pharma (PPLPHARMA.NS). The cockpit's measured peer set (industry) also includes Tibet Rhodiola Pharmaceutical (600211.SS), Anhui Anke Biotechnology (Group) (300009.SZ), Pfizer (PFIZER.NS), CSPC Hunan Jingfeng Pharmaceutical (000908.SZ), Dermapharm (DMP.DE), Alivus Life Sciences (ALIVUS.NS).
Is Cohance Lifesciences expensive compared with its peers?
On forward p/e it trades at 96.3× against a peer median of 15.7×, 2nd most expensive of 20 in its peer set.
How has Cohance Lifesciences stock performed?
Over six months to 18 Nov 2026 the shares returned +6.5% against -12.4% for the median peer; over one year -33.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.